SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Corey J. Langer*, Mary W. Redman, James L. Wade, Charu Aggarwal, Jeffrey D. Bradley, Jeffrey Crawford, Philip J. Stella, Mark H. Knapp, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Karen Kelly, David R. Gandara, Vassiliki A. Papadimitrakopoulou

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)'. Together they form a unique fingerprint.

Medicine and Dentistry

INIS

Biochemistry, Genetics and Molecular Biology